During 2021, the impact of COVID-19 pandemic on the life science industry moved on from initial shock to acceptance and finding a way forward. Throughout the year, COVID has been ever present, but the industry has managed the situation well. Moving forward the sector will have to deal with the after-effects, as restrictions are removed, to leverage the benefits of the creative technical solutions invented for pandemic use, and the reconstruction of in-person interactions.

Read about a booming capital market, promising scale up within gene therapy and new ways to interact with regulators and auditors - in the current issue of Nordic Life Science Magazine, as our CEO Johan Strömquist shares his thoughts on the past year and what’s on the horizon for the life science industry in the Nordics.

Click to read

The Author

Johan Strömquist 



Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.